Quince Therapeutics, Inc.
QNCX
$1.22
-$0.04-3.18%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -83.98M | -56.98M | -49.03M | -60.71M | -56.83M |
| Total Depreciation and Amortization | 142.00K | 119.00K | 169.00K | 178.00K | 186.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 29.57M | 16.10M | 11.11M | 25.01M | 25.22M |
| Change in Net Operating Assets | 12.84M | 2.27M | 1.92M | 2.37M | -484.00K |
| Cash from Operations | -41.43M | -38.50M | -35.83M | -33.15M | -31.90M |
| Capital Expenditure | -352.00K | -481.00K | -453.00K | -366.00K | -257.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 23.58M | 26.50M | 35.36M | 24.26M | 22.17M |
| Cash from Investing | 23.23M | 26.02M | 34.91M | 23.89M | 21.91M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 17.91M | 15.88M | 14.50M | 122.00K | 225.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 0.00 | -5.00M | -5.00M | -5.00M |
| Cash from Financing | 17.91M | 15.88M | 9.50M | -4.88M | -4.78M |
| Foreign Exchange rate Adjustments | -114.00K | 375.00K | 356.00K | 96.00K | 231.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -403.00K | 3.78M | 8.94M | -14.04M | -14.54M |